Abstract:Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used in clinical practice for the management of type 2 diabetes mellitus. However, the extremely short half-life of GLP-1 and the need for subcutaneous administration limit its clinical application. Thus, half-life extension and alternative delivery methods are highly desired. DARPin domains with high affinity for human serum albumin (HSA) have been selected for the half-life extension of therapeutic peptides and proteins. In the present study, novel trivalent fusion proteins as long-acting GLP-1 receptor agonists with potential for oral delivery were computationally engineered by incorporating a protease-resistant modified GLP-1, an anti-human serum albumin DARPin, and an approved cell-penetrating peptide (Penetratin, Tat, and Polyarginine) linked either by rigid or flexible linkers. Theoretical studies and molecular dynamics simulation results suggested that mGLP1-DARPin-Pen has acceptable quality and stability. Moreover, the potential affinity of the selected fusion proteins for GLP-1 receptor and human serum albumin was explored by molecular docking. The recombinant construct was cloned into the pET28a vector and expressed in Escherichia coli. SDS-PAGE analysis of the purified fusion protein matched its molecular size and was confirmed by western blot analysis. The results demonstrated that the engineered fusion protein could bind HSA with high affinity. Importantly, insulin secretion assays using a mouse pancreatic β-cell line (β-TC6) revealed that the engineered trivalent fusion protein retained the ability to stimulate cellular insulin secretion. Immunofluorescence microscopy analysis indicated the CPP-dependent cellular uptake of mGLP1-DARPin-Pen. These findings demonstrated that mGLP1-DARPin-Pen is a highly potent oral drug candidate that could be particularly useful in the treatment of type 2 diabetes mellitus.Communicated by Ramaswamy H. Sarma.

High cell density cultivation of recombinant Escherichia coli for prodrug of recombinant human GLPs production

High-level Production of a Fungal Β-Glucosidase with Application Potentials in the Cost-Effective Production of Trichoderma Reesei Cellulase

One-Step Purification of a Fusion Protein of Glucagon-Like Peptide-1 and Human Serum Albumin Expressed in Pichia pastoris by an Immunomagnetic Separation Technique

Expression of Human Globular Adiponectin-Glucagon-like Peptide-1 Analog Fusion Protein and Its Assay of Glucose-Lowering Effect in Vivo.

High‐level Production of Soluble Pyrroloquinoline Quinone‐dependent Glucose Dehydrogenase in Escherichia Coli

High-Level Soluble Expression of Higf-1 Fusion Protein in Recombinant Escherichia Coli

Engineering of a Pichia pastoris Expression System for High-Level Secretion of HSA/GH Fusion Protein

Synthesis of the extracellular domain of GLP-1R by chemical and biotechnological approaches

Split Ssp DnaB Mini-Intein-mediated Production of Recombinant Human Glucagon-Like Peptide-1/7-36.

RSM optimization of HSA/IL1Ra in Pichia pastoris overexpression strain and study of its in vivo activity in reducing hyperglycemia of GK rats.

Engineering of a Biologically Active Glycosylated Glucagon-Like Peptide-1 Analogue

Engineering a Pharmacologically Superior Form of Granulocyte-Colony-stimulating Factor by Fusion with Gelatin-Like-protein Polymer.

Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris

High Yield And Cost-Effective Production Of Poly(Gamma-Glutamic Acid) With Bacillus Subtilis

High yield and cost-effective production of poly(γ-glutamic acid) with Bacillus subtilis

Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist

A site-specific genomic integration strategy for sustained expression of glucagon-like peptide-1 in mouse muscle for controlling energy homeostasis.

Biochemotaxis-Oriented Engineering Bacteria Expressing GLP-1 Enhance Diabetes Therapy by Regulating the Balance of Immune

Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris.

A new trivalent recombinant protein for type 2 diabetes mellitus with oral delivery potential: design, expression, and experimental validation

Glutamate as a non-conventional substrate for high production of the recombinant protein in Escherichia coli